The Latin American Therapeutic Vaccines Market size is estimated to grow USD 1618.98 Million by 2025, from the current value of USD 361.06 Million in 2020, growing at a CAGR of 35% between 2020 to 2025.
In the pipeline, several approaches are being developed to boost the immune response to various infectious and cancerous cells. There are presently close to 120 new vaccines in the pipeline of various multinational companies across the globe set to hit the market in the next few years. Added to this, the vaccine market is rather concentrated on both supply and demand sides. It is highly regulated and mostly dependent on public purchasers and donor policies. It has very distinct features that increase the complexity of assessing and understanding pricing and procurement in their context.
Coming to Latin America, Sanofi Pasteur, the vaccines division of Sanofi, announced that Brazil had granted regulatory approval to Dengvaxia®, representing the third successful licensure of the dengue vaccine, which was also approved in Mexico and the Philippines earlier in 2015. This, because Brazil is the fifth most populated globally and first in Latin America, is plagued by 1.4 million dengue patients. The remaining countries in Latin America also have a natural threat as they lie in the tropical Amazon basin, making them a hotbed for various epidemics.
An increase in funding’s from the government for vaccine development, a rise in investments by the major market players, rising prevalence of the disease, technological advancements, initiatives by NGOs are some of the factors that are propelling the market growth. However, massive capital expenditures and stringent regulatory policies, and high costs associated with treatment are few factors inhibiting the market's growth.
This research report on the Latin American Therapeutic Vaccines Market segmented and sub-segmented into the following categories:
By Disease Type:
By Country:
Companies playing a notable role in the Latin American Therapeutic Vaccines Market covered in this report are GlaxoSmithKline, plc, Merck and Company, Bavarian Nordic, CSL Limited, Emergent BioSolutions Inc., Novartis AG, Johnson and Johnson, MedImmune, LLC, Pfizer, Inc., and Sanofi Pasteur.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.1 Introduction
2.2 Analysis Design
2.3 Research Phases
2.3.1 Secondary Research
2.3.2 Primary Research
2.3.3 Econometric Modelling
2.3.4 Expert Validation
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 By Disease Type
5.1.1 Autoimmune Disease Vaccines
5.1.2 Cancer Vaccines
5.1.2.1 Multikine
5.1.2.2 PR1 Peptide
5.1.2.3 TroVax
5.1.2.4 CYT004-MelQbG10
5.1.3 Neurological Disease Vaccines
5.1.3.1 ACC- 001
5.1.3.2 CAD 106
5.1.3.3 Parkinson's Disease Vaccine
5.1.3.4 Alzheimer's Disease
5.1.4 Infectious Disease Vaccines
5.1.4.1 Hepatitis C
5.1.4.2 HIV/AIDS
5.1.4.3 Other Infectious Disease
6.1 Introduction
6.2 Brazil
6.3 Argentina
6.4 Mexico
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 GlaxoSMithKline plc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Merck and Company
8.3 Bavarian Nordic
8.4 CSL Limited
8.5 Emergent Biosolutions Inc.
8.6 Novartis AG
8.7 Johnson and Johnson
8.8 MedImmune LLC
8.9 Pfizer Inc.
8.10 Sanofi Pasteur
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
Related Reports
